Abstract

Melanoma is an aggressive tumor with still poor therapy outcomes. δ-tocotrienol (δ-TT) is a vitamin E derivative displaying potent anti-cancer properties. Previously, we demonstrated that δ-TT triggers apoptosis in human melanoma cells. Here, we investigated whether it might also activate paraptosis, a non-canonical programmed cell death. In accordance with the main paraptotic features, δ-TT was shown to promote cytoplasmic vacuolization, associated with endoplasmic reticulum/mitochondrial dilation and protein synthesis, as well as MAPK activation in A375 and BLM cell lines. Moreover, treated cells exhibited a significant reduced expression of OXPHOS complex I and a marked decrease in oxygen consumption and mitochondrial membrane potential, culminating in decreased ATP synthesis and AMPK phosphorylation. This mitochondrial dysfunction resulted in ROS overproduction, found to be responsible for paraptosis induction. Additionally, δ-TT caused Ca2+ homeostasis disruption, with endoplasmic reticulum-derived ions accumulating in mitochondria and activating the paraptotic signaling. Interestingly, by using both IP3R and VDAC inhibitors, a close cause-effect relationship between mitochondrial Ca2+ overload and ROS generation was evidenced. Collectively, these results provide novel insights into δ-TT anti-melanoma activity, highlighting its ability to induce mitochondrial dysfunction-mediated paraptosis.Graphic δ-tocotrienol induces paraptotic cell death in human melanoma cells, causing endoplasmic reticulum dilation and mitochondrial swelling. These alterations induce an impairment of mitochondrial function, ROS production and calcium overload.

Highlights

  • Cutaneous melanoma is the third most common type and the deadliest form of skin cancer [1]

  • Since paraptosis is known to be dependent on protein synthesis, it can be inhibited by cycloheximide, a translation inhibitor; on the other hand, it is not modulated by caspases, it cannot be blocked by inactivation of these proteins

  • Inherent or acquired drug resistance frequently leads to therapeutic failure, with patients experiencing tremendous adverse effects in the [3,4,5,6,7]

Read more

Summary

Introduction

Cutaneous melanoma is the third most common type and the deadliest form of skin cancer [1]. On the other hand, advanced melanomas (stages III and IV) are highly aggressive, and currently available therapeutic strategies include chemotherapy (i.e. dacarbazine), targeted therapy (i.e. vemurafenib, dabrafenib, trametinib, encorafenib, binimetinib and cobimetinib) and immunotherapy (i.e. ipilimumab, pembrolizumab, nivolumab and atezolizumab). These approaches are characterized by a low success rate due to the development of drug resistance [3,4,5,6,7]. Most of these treatments are often accompanied by severe side effects [8, 9] In this context, more effective and better-tolerated anti-melanoma options need to be urgently identified

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call